SETD1A: A Potential Drug Target and Biomarker (G9739)

Target Name: SETD1A

NCBI ID: G9739

SETD1A

SETD1A: A Potential Drug Target and Biomarker

Sertraline (SETD1A) is a medication that is currently being investigated as a potential treatment for various psychiatric disorders, including depression, anxiety, and PTSD. It works by selectively targeting serotonin receptors, which are found throughout the brain and play a crucial role in mood, emotion, and behavior.

SETD1A is a N-methyl-D-aspartate (NMDA) receptor antagonist, which means that it works by blocking the action of serotonin, a neurotransmitter that is involved in the transmission of mood and emotion. Serotonin is produced by the body's own serotonin-producing neurons and is involved in the regulation of a wide range of physiological processes, including mood, appetite, and sleep.

In depression, high levels of serotonin can contribute to the symptoms of depression, including low mood, loss of interest in activities, and changes in appetite and sleep patterns. SETD1A is thought to work by blocking the action of serotonin receptors to reduce these symptoms.

SETD1A is also being investigated as a potential biomarker for depression. Measurement of brain activity in individuals with depression can be difficult, as depression can cause changes in brain activity that are difficult to detect. However, researchers have found thatSETD1A levels are often lower in individuals with depression than in those without the condition.

In addition to its potential as a treatment for depression, SETD1A is also being investigated as a potential biomarker for the disease. Studies have shown thatSETD1A levels are often lower in individuals with depression than in those without the condition, and that the levels of SETD1A may be a useful diagnostic marker for depression.

While the exact mechanism of SETD1A's effects on serotonin receptors is not fully understood, it is thought to work by blocking the action of serotonin to reduce the levels of a neurotransmitter called homoserotonin in the brain. Homoserotonin is produced by the body's own serotonin-producing neurons and can contribute to the symptoms of depression. By blocking the action of serotonin receptors, SETD1A may be able to reduce the levels of homoserotonin in the brain, which could lead to the therapeutic effects of SETD1A.

In conclusion, SETD1A is a promising drug target and biomarker for depression. Its ability to selectively target serotonin receptors and its potential as a treatment for depression make it an attractive candidate for further study. Further research is needed to fully understand the exact mechanism of SETD1A's effects on serotonin receptors and to determine its potential as a drug and biomarker for depression.

Protein Name: SET Domain Containing 1A, Histone Lysine Methyltransferase

Functions: Histone methyltransferase that catalyzes methyl group transfer from S-adenosyl-L-methionine to the epsilon-amino group of 'Lys-4' of histone H3 (H3K4) via a non-processive mechanism (PubMed:25561738, PubMed:12670868). Part of chromatin remodeling machinery, forms H3K4me1, H3K4me2 and H3K4me3 methylation marks at active chromatin sites where transcription and DNA repair take place (PubMed:29937342, PubMed:31197650, PubMed:32346159). Responsible for H3K4me3 enriched promoters and transcriptional programming of inner mass stem cells and neuron progenitors during embryogenesis (By similarity) (PubMed:31197650). Required for H3K4me1 mark at stalled replication forks. Mediates FANCD2-dependent nucleosome remodeling and RAD51 nucleofilaments stabilization at reversed forks, protecting them from nucleolytic degradation (PubMed:29937342, PubMed:32346159). Does not methylate 'Lys-4' of histone H3 if the neighboring 'Lys-9' residue is already methylated (PubMed:12670868)

The "SETD1A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SETD1A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets